Heart attack patients may get a powerful new tool to slash cholesterol

NCT ID NCT07684469

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding a drug called inclisiran to standard cholesterol-lowering therapy (statins) helps people who recently had a heart attack or unstable angina lower their LDL ('bad') cholesterol more than statins alone. About 300 adults in Saudi Arabia will receive either inclisiran plus standard care or standard care alone, and their cholesterol levels will be measured over several months. The goal is to see if this combination can more aggressively reduce cholesterol and potentially prevent future heart problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
inclisiran
What this could lead to
If successful, this approach could become a standard add-on treatment to prevent future heart attacks by aggressively lowering cholesterol.
What could go wrong
This is a Phase 4 trial in a specific region, so results may not apply globally. Inclisiran may cause injection-site reactions or not provide additional benefit over statins alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.